Menu

Fungus Versus Plant

The crop-destroying gray mold fungus uses RNA weapons to disable plant defenses and invade.

Oct 3, 2013
Ruth Williams

Botrytis cinerea on Riesling grapesWIKIMEDIA, TOM MAACKStrike, counter-strike, and so on, ad infinitum. The relationship between pathogens and their hosts is a never-ending, continuously evolving battle. And scientists have now discovered that one plant pathogen even hijacks its host’s defense system for its own use. According to a report published online today (October 3) in Science, the gray mold fungus, Botrytis cinerea, deploys small, non-coding RNAs (sRNAs) that subvert the plant’s silencing machinery, forcing it to suppress the expression of host immune system genes.

“We know we’re always going to see defense and counter-defense,” said David Baulcombe, a professor of plant sciences at Cambridge University, who was not involved in the work. “But what is novel about this one is that . . . the counter-defense system is firstly an RNA molecule, which is new, and secondly . . . it moves from a fungal to a plant cell and that, too, is quite novel.”

Hailing Jin, a professor of plant pathology and microbiology at the University of California, Riverside, who led the new study, was intrigued to discover that a fungus uses RNAs to attack plants. She had been searching for sRNAs induced upon infection, but had assumed that they would be produced by the plants themselves. After all, RNA silencing, in which sRNAs bind to protein-coding messenger RNAs and suppress their expression, is a mechanism used by plants to inhibit the activity of invading foreign genes. “I was focusing on the plants’ immune responses against pathogens,” she explained, “so I was looking at plant endogenous small RNAs that are induced by pathogen infection.”

But she found that a small proportion of the infection-induced sRNAs were “a 100 percent match to the Botrytis sequence,” she said. “It was a surprise to us.”

Of 832 Botrytis sRNAs that Jin found were induced upon infection of tomato or Arabidopsis plants, 73 were predicted to silence genes of the host plants. Jin focused on three particular sRNAs whose targets were indicated to be mRNAs involved in both plants’ immune responses.

First, the researchers showed that the target immune mRNAs were indeed suppressed upon infection of the plants by the fungus, and that blocking the target mRNAs experimentally made the plants more susceptible to infection. Further, when the sRNA binding sites in the target mRNAs were mutated, their suppression by the Botrytis sRNAs was abolished.

The team then showed that the fungal sRNAs associated with and utilized the plant’s own mRNA silencing machinery, and that plants in which silencing machinery was mutated were consequently more resistant to Botrytis infection.

The ultimate confirmation that the fungal sRNAs target and suppress the host plants’ immune system genes, however, would be “to test whether a plant engineered to express alleles of the [target] genes that are refractory to the action of the [fungal] small RNAs are more resistant, ” said Jonathan Jones, a plant scientist at The Sainsbury Laboratory in Norwich, UK, who did not participate in the work. Not only would this be “the acid test of their hypothesis,” he said, it could point to an effective disease-control strategy for agricultural use.

And coming up with resistant plants could be extremely lucrative. Botrytis cinerea, or gray mold, attacks more than 200 species of fruit and vegetables, and causes billions of dollars of damage worldwide each year, said Jin.

Although Botrytis is  costly and destructive, the fungus does have one saving grace. It rots grapes to a degree that’s perfect for producing exceptional desert wines, such as Sauternes—hence the pest’s other name: nobel rot.  Jones said the new findings suggest  “that, heaven forefend, Botrytis is genetically manipulating the grapes before we drink them.”

A. Weiberg et al., "Fungal small RNAs suppress plant immunity by hijacking host RNA interference pathways," Science, 342: 118-123, 2013.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.